Skye Bioscience, Inc. (SKYE) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US83086J2006
Skye Bioscience, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -58.16 m USD |
| EBIT | -57.80 m USD |
| Net income | -55.92 m USD |
| Diluted EPS – continuing operations | -1.41 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
More stocks
- PANACEA LIFE SCIENCES HOLDINGS, INC. (PLSH)
- Osung Advanced Materials Co. Ltd (052420.KQ)
- GEN Restaurant Group, Inc. (GENK)
- SciBase Holding AB (publ) (SCIB.ST)
- Armlogi Holding Corp. (BTOC)
- AppTech Payments Corp. (APCX)
- DESTINY MEDIA TECHNOLOGIES INC (DSNY)
- Clean Vision Corp (CLNV)
- SUNRISE REAL ESTATE GROUP INC (SRRE)
- SPECIFICITY, INC. (SPTY)
- Perfect Moment Ltd. (PMNT)
- GD Culture Group Ltd (GDC)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.